Bristol Stock Based Compensation To Revenue from 2010 to 2024

BMY Stock  USD 59.94  0.72  1.22%   
Bristol Myers Stock Based Compensation To Revenue yearly trend continues to be fairly stable with very little volatility. Stock Based Compensation To Revenue will likely drop to 0.01 in 2024. Stock Based Compensation To Revenue is a metric that compares the total value of stock-based compensation granted by Bristol Myers Squibb to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. View All Fundamentals
 
Stock Based Compensation To Revenue  
First Reported
2010-12-31
Previous Quarter
0.01150958
Current Value
0.00872
Quarterly Volatility
0.00332944
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Bristol Myers financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bristol Myers' main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.3 B, Interest Expense of 1.2 B or Selling General Administrative of 3.6 B, as well as many indicators such as Price To Sales Ratio of 2.98, Dividend Yield of 0.0374 or PTB Ratio of 6.92. Bristol financial statements analysis is a perfect complement when working with Bristol Myers Valuation or Volatility modules.
  
Check out the analysis of Bristol Myers Correlation against competitors.

Latest Bristol Myers' Stock Based Compensation To Revenue Growth Pattern

Below is the plot of the Stock Based Compensation To Revenue of Bristol Myers Squibb over the last few years. It is a metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. Bristol Myers' Stock Based Compensation To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bristol Myers' overall financial position and show how it may be relating to other accounts over time.
Stock Based Compensation To Revenue10 Years Trend
Slightly volatile
   Stock Based Compensation To Revenue   
       Timeline  

Bristol Stock Based Compensation To Revenue Regression Statistics

Arithmetic Mean0.01
Geometric Mean0.01
Coefficient Of Variation29.44
Mean Deviation0
Median0.01
Standard Deviation0
Sample Variance0.000011
Range0.0121
R-Value0.33
Mean Square Error0.000011
R-Squared0.11
Significance0.22
Slope0.0002
Total Sum of Squares0.0002

Bristol Stock Based Compensation To Revenue History

2024 0.00872
2023 0.0115
2022 0.009901
2021 0.0126
2020 0.0183
2019 0.0169
2018 0.009796

About Bristol Myers Financial Statements

Bristol Myers investors use historical fundamental indicators, such as Bristol Myers' Stock Based Compensation To Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bristol Myers. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Stock Based Compensation To Revenue 0.01  0.01 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Bristol Stock Analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.